(VSAR) Conference Call to Discuss Six Month VRS-317 Phase 2a Clinical Trials

Conference Call and Webcast Scheduled at 5:00 p.m. EDT on June 23, 2014

Data Presented During Poster Session at ICE/ENDO 2014

MENLO PARK, Calif., June 9, 2014  — Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, June 23, 2014 at 5:00 p.m. EDT (4:00 p.m. CDT).

During the call, Versartis management will discuss the results, including 6 month height velocity and safety, from the Company’s completed VERTICAL trial, a Phase 1b/2a study of VRS-317 in naïve pre-pubertal children with GHD. The results will be presented at a poster presentation that afternoon from 2:00 p.m. to 4:00 p.m. EDT (1:00 p.m. to 3:00 p.m. CDT) during the International Congress of Endocrinology and Endocrine Society’s Annual Meeting and Expo at the McCormick Place West in Chicago, IL. The poster is entitled “Safety and Efficacy Results of a 6 Month, Randomized, Multi-Center Trial of a Novel Long-Acting rhGH (VRS-317) in Naïve to Treatment, Pre-Pubertal Children with Growth Hormone Deficiency (GHD).” The results will also be announced in a press release at the start of the poster session.

Currently, there are seven marketed rhGH products in the US for the treatment of GHD. However, a key limitation of these products is the burden of daily injections, which can compromise compliance and lead to suboptimal treatment outcomes. As such, the Company believes that there is a significant unmet need for an improved therapeutic option for both pediatric and adult GHD patients. Versartis previously demonstrated in a Phase 1a trial in GHD adults the potential for monthly dosing in this patient population as published in Yuen et al, JCEM 2013. VRS-317 is being developed to provide up to once-monthly dosing and has the potential to improve patients’ compliance to rhGH therapy and overall treatment outcomes.

Conference Call and Webcast

Versartis will hold a conference call on Monday, June 23, 2014 at 5:00 p.m. EDT (4:00 p.m. CDT). The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.versartis.com.

After the live webcast, the call will remain available on the Versartis website, www.versartis.com, for 90 days. In addition, a telephonic replay of the call will be available until July 7, 2014. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay conference ID number 13584528.

The VRS-317 VERTICAL Trial

The Versartis Trial In Children to Assess Long-Acting Growth Hormone (VERTICAL) study was conducted in approximately 25 US pediatric endocrinology centers and enrolled 64 naïve-to-treatment, pre-pubertal children with GHD that was documented by auxologic criteria and two GH stimulation tests.

The VERTICAL trial of VRS-317 consists of two stages: a single ascending dose stage (Phase 1b) to determine the safety, PK and PD of VRS-317 doses and to enable selection of dose regimens, which were then used in the repeat dose second stage (Phase 2a) to obtain 6-month height velocity results.

The primary endpoint of the Phase 2a study is mean 6-month height velocity. GHD was diagnosed by short stature (HT-SDS < -2), delayed bone age, paired GH stimulation tests (GHmax ≤ 10 ng/mL), a low IGF-I (IGF-I SDS < -1) and absence of other conditions to cause poor growth. Initially, 48 subjects (8/dose cohort) were enrolled in the Phase 1b stage and received single doses at one of six VRS-317 dose levels (0.8 to 6.0 mg/kg). Based on observed PK/PD results, 64 subjects were enrolled in the Phase 2a stage and randomized into three cohorts to evaluate 5.0 mg/kg monthly, 2.5 mg/kg semi-monthly or 1.15 mg/kg weekly. At the start of repeat dosing, the subjects (37M/27F) had a mean (SD) age of 7.8 (2.4) years, HT-SDS of -2.5 (0.5) and IGF-I SDS of -1.7 (0.8).

Results from the completed Phase 1b single ascending dose stage of the study were reported on September 22, 2013 at the 9th Joint Meeting of Paediatric Endocrinology in Milan and announced in the following press release: http://ir.versartis.com/releasedetail.cfm?ReleaseID=831885

About Versartis

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The Company has recently completed a Phase 2a clinical trial evaluating weekly, semi-monthly and monthly dosing regimens of VRS-317 in children with GHD. Further information on Versartis can be found at www.versartis.com.

Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “believes,” “potential,” “will” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success of the Phase 2a stage of our on-going Phase 1b/2a clinical, the potential outcome of our discussions with the FDA and EMA, the potential resumption of our development of VRS-317 in adults with GHD, potential market opportunities in GHD. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our success being heavily dependent on VRS-317; VRS-317 being a new chemical entity; serious adverse side effects, if they are associated with VRS-317; VRS-317 may not have favorable results in later clinical trials or receive regulatory approval; other long-acting rhGH products and product candidates have failed to generate commercial success or obtain regulatory approval; delays in enrollment of patients in our clinical trials could increase our costs and cause delay; VRS-317 may cause serious adverse side effects or have properties that delay or prevent regulatory approval or limit its commercial profile; manufacturing; if approved, risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; the importance of our license of intellectual property from Amunix Operating, Inc. and our need for additional funds to support our operations. We discuss many of these risks in greater detail under the heading “Risk Factors” section contained in our Quarterly Report on Form 10-Q for the 3 months ended March 31, 2014, which is on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CONTACT: Corporate
         Joshua Brumm
         Chief Financial Officer
         (650) 963-8582
         IR@versartis.com

         Investors
         Nick Laudico
         The Ruth Group
         (646) 536-7030
         nlaudico@theruthgroup.com

         Media
         Debra Bannister
         Corporate Communications
         (530) 676-7373
         media@versartis.com

(FIVN) Client Positec to Speak on Developing Super Agents

LAS VEGAS, June 9, 2014  — Five9, Inc. (Nasdaq:FIVN), a pioneer and leading provider of cloud contact center software, will be exhibiting at IQPC Call Center Week, June 11-13, 2014 in Las Vegas. Rhonda Tate, vice president of direct response at Five9 customer Positec, a leading manufacturer of power tools, will lead a session focused on the importance of developing and managing “super agents” to align with multichannel customer care strategies.

TWEET THIS: Join @Five9 at #CallCenterWeek for #multichannel and super agents discussion with @Positec on 6/11 @ 4:45 PDT #vegas

Additionally, Five9 will host demonstrations of the multichannel and social customer care features of the Five9 cloud contact center solution at booth #116. The presentations will take place during the show expo hall hours; attendees who participate in a presentation will receive a Bobble filtered water bottle.

About Five9

Five9 is a leading provider of cloud contact center software, bringing the power of the cloud to thousands of customers and facilitating more than three billion customer interactions annually. Since 2001, Five9 has led the cloud revolution in contact centers, helping organizations of every size transition from premise-based software to the cloud. With its extensive expertise, technology, and ecosystem of partners, Five9 helps businesses take advantage of secure, reliable, scalable cloud contact center software to create exceptional customer experiences, increase agent productivity and deliver tangible business results. For more information visit www.five9.com. All product and company names mentioned are the property of their respective owners.

CONTACT: Analyst & Media Contact:

         Julie Huang
         Five9 Inc.
         925-285-9126
         Julie.Huang@five9.com

(RCPT) Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

– Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment –

– Safety data are supportive of differentiated product profile –

–   Investor conference call and webcast today at 5:00 p.m. EDT (2:00 p.m. PDT) –

SAN DIEGO, June 9, 2014  — Receptos, Inc. (Nasdaq:RCPT) today announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.

The randomized, double-blind study assessed the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1.0 mg) of RPC1063 against placebo in 258 patients with RMS across 77 sites in 13 countries.   The primary endpoint of the trial was the reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions determined by MRI from week 12 to week 24 of study treatment, a standard endpoint for Phase 2 trials in this indication. Patients on RPC1063 experienced a statistically significant reduction in GdE lesions of 86% at both 0.5 mg and 1.0 mg compared to patients on placebo (p-values <0.0001 for each dose group compared to placebo). Secondary endpoints measuring effects on other MRI parameters were also positive and statistically significant (p<0.0001 for each dose group compared to placebo). Although this Phase 2 portion of the trial was not powered to detect a statistically significant difference between RPC1063 treatment arms and placebo on annualized relapse rate (ARR), there was a favorable trend for both RPC1063 dose groups. The detailed results of the Phase 2 portion of the RADIANCE trial are expected to be presented at a major scientific meeting in coming months.

Safety and tolerability data from the trial provide support for a differentiated, potential best-in-class profile. The overall adverse event profile appeared relatively similar between the RPC1063 dose groups and placebo with no concerning safety signals for patients receiving RPC1063. First dose changes in heart rate in patients receiving RPC1063 were generally modest (maximum mean reduction <2 beats per minute compared to baseline) with no patients dropping below 45 beats per minute during the first six hours after administration, which is consistent with the findings of the Company’s earlier thorough QT study.   Rates of liver transaminase elevations observed in patients receiving RPC1063 were low relative to agents with similar mechanisms of action on the market or in clinical development, and supportive of a favorable hepatic safety profile.

“The results of this trial demonstrated a significant treatment effect of RPC1063 at both doses, consistent with other molecules in the class,” said Jeffrey Cohen, M.D., Principal Investigator of the RADIANCE trial and director of the Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research. “The results also showed a favorable overall safety profile, particularly in the critical areas of cardiovascular and hepatic side effects. The ongoing Phase 3 trial has been designed to confirm and extend these results.”

Receptos initiated the Phase 3 portion of the RADIANCE trial under a Special Protocol Assessment (SPA) with the FDA in December 2013. The Phase 3 portion of the trial, which is currently enrolling patients, is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex®) in 1,200 patients with RMS.

“The positive results of the Phase 2 portion of RADIANCE exceeded our expectations with respect to the differentiation thesis for RPC1063,” said Faheem Hasnain, President and Chief Executive Officer of Receptos. “Based on our analysis of the Phase 2 dataset, we believe that RPC1063 has the opportunity to be the best-in-class S1P receptor modulator. Our Phase 3 program is now well underway, positioning the program as the most advanced S1P receptor modulator in development for relapsing multiple sclerosis. In addition, we believe that RPC1063 may have promise in other therapeutic areas, and we continue to look forward to the results of TOUCHSTONE, our Phase 2 trial of RPC1063 in ulcerative colitis, in the fourth quarter of 2014.”

Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) 

The Receptos management team will host a teleconference and webcast to discuss the information in this press release. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), conference ID 58382320. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 58382320.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company’s lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

Forward-Looking Statements

Statements contained in this release, other than statements of historical fact, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “expects,” “believes,” “may,” “intends,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as RPC1063 constitute forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation consistency of trial results to date with further trial results, the Company’s ability to adequately and timely recruit and enroll patients in its clinical trials, as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company’s SEC filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. All forward-looking statements contained in this release speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@Receptos.com

         Andrew McDonald
         LifeSci Advisors, LLC
         (646) 597-6987
         andrew@lifesciadvisors.com

(GLRI) SeeThruEquity Initiates Research Coverage, Target Price of $13.37

New York, NY / June 9, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Glori Energy, Inc. (“Glori”) (NASDAQ: GLRI), an energy technology company.

“We are pleased to add Glori Energy to our research coverage universe and are intrigued by its proprietary AERO(TM) System, a highly efficient, biotechnology process for increasing oil recovery from existing reservoirs. Only one-third of all oil discovered in a typical reservoir is recoverable using conventional technologies; the rest remains trapped. Glori’s AERO technology recovers trapped oil by stimulating a reservoir’s native microorganisms to sustainably increase the ultimate incremental recovery. To further validate the technology and gain critical field experience, Glori has provided its AERO System as a service to third party E&P companies. The company is now beginning the process of applying its technology to fields it acquires and redevelops onshore in the U.S.,” commented Ajay Tandon, CEO of SeeThruEquity. “We look forward to following the company’s progress and are initiating coverage with a price target of $13.37 per share.”

Additional investment highlights are as follows:

– Biotech meets oil production with AERO(TM) technology. Glori’s AERO(TM) (Activated Environment for Recovery of Oil) System is a highly efficient, environmentally sustainable, cost-effective solution for increasing oil recovery from existing reservoirs. The AERO(TM) System enhances production from waterflooded fields by stimulating a reservoir’s naturally occurring microbes to improve water sweep and oil mobility. The addition of the AERO(TM) System to an ongoing waterflood can deliver the industry’s most cost-effective and successful Enhanced Oil Recovery (“EOR”) technology available today, with potential ultimate incremental recovery of an additional 9-12% of the Original Oil in Place (“OOIP”). Glori has completed a dozen projects around the globe with very promising results, demonstrating 60-100% growth in oil production after six months of AERO(TM) implementation.

– “Arbitrage” on conventional oil well asset valuation methodology. Glori’s next major avenue of growth is its oil assets acquisition strategy. The company plans to acquire mature, producing fields located onshore in North America that conform to the AERO(TM) screening criteria. By capturing 100% of the AERO(TM) -related production increases and enhancing property returns using operating leverage, Glori plans to create a growing portfolio of producing properties, with predictable revenue and cash flow streams and significantly extended economic limits. Using an AERO(TM) “arbitrage” to increase production, Glori will have acquired the properties at prices far below the value after AERO(TM) implementation. Glori is focusing its current acquisition efforts in Texas and the Illinois Basins, and plans to make three acquisitions a year over the 2014-2018E timeframe. Even with its rigorous “reservoir up” data research and analysis screening process, Glori reports over 200 actionable projects under review in the three basins.

– Services revenue provides diversification, valuable experience. Glori also derives revenues by providing its AERO(TM) System as a service offering to third party exploration and production companies. Glori utilizes the identical process and technology in its service segment as it intends to use in its proprietary properties. Glori has projects in process in North America, South America and the Middle East, with an impressive roster of clients.

The report is available here: GLRI Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

Please review important disclosures on our website at www.seethruequity.com.

About Glori Energy Inc.
Glori Energy Inc. is a Houston-based energy technology company known for its proprietary AEROTM System, a highly efficient, biotechnology process for increasing oil recovery from existing reservoirs. Only one-third of all oil discovered in a typical reservoir is recoverable using conventional technologies; the rest remains trapped. Glori’s AERO technology recovers trapped oil by stimulating a reservoir’s native microorganisms to sustainably increase the ultimate incremental recovery. Glori applies its technology to fields the company acquires and redevelops onshore in the U.S., and also provides its AERO System as a service to third party E&P companies.

For more information, visit www.GloriEnergy.com.

About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

(HITT) to be Acquired by (ADI)

Analog Devices, Inc. (NASDAQ:ADI), a global leader in high-performance semiconductors for signal processing applications, and Hittite Microwave Corporation (NASDAQ:HITT), an innovative designer and manufacturer of high performance integrated circuits, modules, subsystems and instrumentation for RF, microwave and millimeter wave applications, today announced that the two companies have entered into a definitive agreement whereby ADI will acquire Hittite for $78 per share in cash. The closing price of Hittite’s common stock on June 6, 2014 was $60.56 per share.

This agreement reflects a total enterprise value for Hittite of approximately $2 billion. ADI expects to fund the acquisition through a combination of cash on hand and short-term debt financing. The Boards of Directors of each company have approved the transaction, which is expected to close near the end of ADI’s third fiscal quarter of 2014, subject to regulatory approvals and other customary closing conditions.

The transaction is expected to be accretive to ADI’s non-GAAP earnings per share.

“Hittite’s strength in RF, microwave, and millimeter wave technology complements ADI’s RF and signal conversion expertise,” said Vincent Roche, ADI President and CEO. “Our combined capabilities will enable us to bring more complete solutions to our customers and address more of the industrial, communications infrastructure, and automotive markets.”

“We welcome the very talented Hittite team, as we together leverage our strong product portfolios and customer relationships to create greater value for all our stakeholders,” said Mr. Roche.

Rick D. Hess, President and Chief Executive Officer of Hittite added, “We are delighted to join forces with ADI, a premier company that shares Hittite’s passion for solving complex challenges for customers. I look forward to joining Analog Devices and I am confident our combined efforts will accelerate the course of innovation throughout cellular and microwave communications infrastructure, automotive, industrial instrumentation, aerospace and defense.”

ADI also reaffirmed financial guidance for its third quarter of fiscal year 2014, for revenue to increase in the range of 1% to 5%, and excluding any one-time items, for diluted earnings per share to be in the range of $0.60 to $0.64.

Credit Suisse acted as exclusive financial advisor to Analog Devices, and WilmerHale served as its legal advisor. Deutsche Bank acted as exclusive financial advisor to Hittite. Foley Hoag acted as legal advisor.

Conference Call Information

ADI and Hittite will host a joint conference call on June 9, 2014 at 8am ET to discuss the acquisition. Presentation slides accompanying the webcast are also accessible at investor.analog.com.

Investors may join via webcast, accessible at investor.analog.com, or by telephone (call 800-859-9560 ten minutes before the call begins and provide the password “ADI”).

A replay of the call will be made available and may be accessed for up to two weeks by dialing 855-859-2056 (replay only) and providing the conference ID: 58177775, or by visiting investor.analog.com.

Important Additional Information Will Be Filed with the Securities and Exchange Commission

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Hittite. At the time the tender offer is commenced, ADI will file with the Securities and Exchange Commission (“SEC”) and mail to Hittite’s stockholders a Tender Offer Statement and Hittite will file with the SEC and mail to its stockholders a Tender Offer Solicitation/Recommendation Statement in connection with the transaction. These documents will contain important information about ADI, Hittite, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available. Investors and security holders will be able to obtain free copies of the Tender Offer Statement, the Tender Offer Solicitation/Recommendation Statement and other documents filed with the SEC by ADI and Hittite through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents from ADI or Hittite by contacting ADI’s Director of Investor Relations at Analog Devices, Inc., One Technology Way, Norwood, Massachusetts 02062; telephone: 781-461-3282 or by contacting Hittite’s Chief Financial Officer at Hittite Microwave Corporation, 2 Elizabeth Drive Chelmsford, Massachusetts 01824; telephone: 978-250-3343.

Forward-Looking Statements

This press release contains forward-looking statements, which address a variety of subjects including, for example, the expected timetable for closing of the transaction between ADI and Hittite, the expected benefits and synergies of the transaction, including the effect of the transaction on ADI’s non-GAAP earnings, ADI’s expected product development and technical advances resulting from the transaction, the availability of debt financing for the transaction and ADI’s guidance for the remainder of its fiscal year 2014. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: the closing of the transaction is subject to the tender of shares by Hittite stockholders representing at least a majority of the outstanding fully-diluted shares; the receipt of regulatory approvals, and other closing conditions, the non-satisfaction of which may delay or prevent the closing of the transaction; higher than expected or unexpected costs associated with or relating to the transaction; the expected benefits, synergies and growth prospects of the transaction may not be achieved in a timely manner, or at all; Hittite’s business may not be successfully integrated with ADI’s following the closing; and disruption from the transaction may adversely affect Hittite’s relationships with its customers, suppliers or employees. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to both ADI’s and Hittite’s filings with the Securities and Exchange Commission, including the risk factors contained in each of ADI’s and Hittite’s most recent Quarterly Reports on Form 10-Q. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

About Analog Devices

Innovation, performance, and excellence are the cultural pillars on which Analog Devices has built one of the longest standing, highest growth companies within the technology sector. Acknowledged industry-wide as the world leader in data conversion and signal conditioning technology, Analog Devices serves over 60,000 customers, representing virtually all types of electronic equipment. Analog Devices is headquartered in Norwood, Massachusetts, with design and manufacturing facilities throughout the world. Analog Devices’ common stock is included in the S&P 500 Index.

About Hittite

Hittite Microwave Corporation (HITT) designs and develops high performance integrated circuits, modules, and subsystems for technically demanding radio frequency (RF) microwave and millimeter wave applications. These applications include cellular, optical, and satellite communications, as well as medical and scientific imaging, industrial instrumentation, aerospace, and defense electronics. With almost 30 years of experience and innovation, Hittite has a deep knowledge of analog, digital and mixed-signal semiconductor technology, from the device level to the design and assembly of complete subsystems.

(INVT) Announces Shareholder Sales Restriction Agreements

(UEPS) Finalizes Recovery of Additional SASSA Implementation Costs

Investor Relations Contact:
Dhruv Chopra
Head of Investor Relations
+1-917-767-6722
dchopra@net1.com
www.net1.com

(LFVN) President & CEO Elected to Direct Selling Association Board of Directors

Robinson Expands His Involvement With The Direct Selling Association

SALT LAKE CITY, June 6, 2014  — LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, today announced that President and CEO Douglas C. Robinson has been elected to the Board of Directors for the Direct Selling Association (DSA). His term began on June 2, 2014 and will last three years.

Robinson’s nomination expands his involvement with the Direct Selling Association, where he has served as a member of the World Federation of Direct Selling Association’s (WFDSA) CEO Council since 2013.

“I am honored to have the opportunity to serve on the Board of Directors of the DSA,” said Robinson. “The associations’ mission is to protect, serve and promote the effectiveness of member companies and the independent business people they represent. It will be a pleasure to work with my fellow Board members to ensure that all member companies are operating with the highest level of business ethics and service to our customers.”

“Directors of the association are recognized leaders within the DSA who command the respect of their colleagues and the public,” said Joseph Mariano, Direct Selling Association President. “LifeVantage has grown significantly under Doug’s leadership and we look forward to further leveraging his leadership and expertise through his service on the DSA Board of Directors.”

About LifeVantage Corporation

LifeVantage Corporation (LFVN), a leader in Nrf2 science and the maker of Protandim^®, the Nrf2 Synergizer^® patented dietary supplement, TrueScience™ Anti-Aging skin care regimen with enhanced Nrf2 technologies, and Canine Health, is a science based network marketing company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (310) 954-1105
         Partner, ICR, INC

(PEGA) Honored by Forbes as One of “America’s 100 Most Trustworthy Companies”

(TREE) Expands Product Offering to Include Student Loan Shopping Experience

Through continued diversification, students can now comparison shop for education loans on LendingTree

CHARLOTTE, N.C., June 6, 2014  — LendingTree has moved into the student loan category, launching a new student loan shopping experience for private student loans.

This is the latest effort in a growing series of product initiatives that LendingTree has recently launched.  Others include reverse mortgages, home equity, personal loans, and a new mobile app.

Through LendingTree’s student loan shopping experience, students or their parents can compare private student loan offers that are customized  to the their requested loan amount and school.  The borrower can then compare loan features including APR range, loan terms, total borrowing costs and monthly payments to find the loan option that best fits their needs. Once they have made a selection, they are then directed to the full application on the lender’s site.

“We are on a mission to help students and their parents become better, more empowered borrowers when it comes time to seek financial aid for school,” said Tamara Kotronis, SVP & GM, Education.  “This experience affords them the opportunity to shop and compare loan offers side-by-side in a consistent manner, and truly find the best fit for their needs.”

According to the College Board, private student loans accounted for 39 percent of undergraduates’ funding and 64 percent of graduate students’ funding in 2012-13, with total education borrowing amounting to over $110 billion. Private student loans help to bridge the gap between college tuition and federal financial aid. Typically, private student loan funds are available earlier than Federal loans and can help fund graduate school when Pell grants aren’t an option. Private student loan rates are dependent on one’s credit profile and may require a co-signer.

For more information, please visit www.lendingtree.com/studentloans.

About LendingTree, LLC
LendingTree, LLC is the nation’s leading online source for competitive home loan offers, empowering consumers during the mortgage, refinance or auto loan process.  LendingTree provides an online marketplace which connects consumers with multiple lenders that compete for their business, as well as an array of online tools and information to help consumers find the best loan. Since inception, LendingTree has facilitated more than 30 million loan requests and $214 billion in closed loan transactions. LendingTree provides access to lenders offering mortgages and refinance loans, home equity loans/lines of credit, and more. LendingTree, LLC is a subsidiary of Tree.com, Inc. (NASDAQ: TREE). For more information go to www.lendingtree.com, dial 800-555-TREE, join our Facebook page and/or follow us on Twitter @LendingTree.

MEDIA CONTACT:
Megan Greuling
(704) 943-8208
Megan.Greuling@tree.com

(VGGL) Platform Launches with Point-Earning on the Web

Viggle Points can now be earned for watching video content online

Viggle Inc. (NASDAQ:VGGL) (“Viggle”), the entertainment marketing and rewards platform, today announced the expansion of its platform integration which allows point-earning on the web. Now consumers can earn Viggle points for watching video content at Wetpaint.com, a leading digital destination and social publishing platform for entertainment fans.

The same technology that allows Viggle point-earning for watching original programming and TV show trailers on Wetpaint can be extended to other third-party properties across the web as well. This creates an ongoing opportunity for Viggle to partner with TV networks and online original content producers, to drive tune in and engagement.

Building on its reputation as an engaging source of entertainment, celebrity and music news, Wetpaint is also expanding its content offering through original videos produced in-house. Wetpaint was acquired by Viggle Inc. in December 2013.

Viggle’s platform consists of the Viggle app, which offers rewards for watching TV, advertisements or listening to music; NextGuide, a personalized TV programming guide and distributed reminder platform; and Wetpaint, an entertainment news and social publishing platform. In March 2014, Viggle Inc. achieved a total reach of 20.8 million.

Marking Viggle’s first points-earning expansion beyond its own mobile app, Wetpaint fans who don’t already belong to Viggle can register for the Viggle Platform on Wetpaint.com. Viggle Points can be earned for watching videos at the site and be redeemed in the recently launched Viggle Store at Vigglestore.com for music downloads, or via the Viggle app for electronics, trips, and gift cards among other items.

“The launch of Viggle point-earning at Wetpaint opens a new chapter in the expansion of the Viggle Platform to engage entertainment fans,” said Greg Consiglio, president and COO of Viggle Inc. “This technology-driven integration further fulfills our vision of allowing entertainment fans to be rewarded for all of their entertainment consumption, no matter where or when it occurs. Viggle members can earn points for watching TV anywhere, listening to and buying music and now for watching videos online.”

About Viggle Inc.

Viggle is an entertainment marketing and rewards platform whose app rewards its members for watching TV shows and discovering new music. The Viggle mobile app has over 4 million users. Since its launch, Vigglers have redeemed over $18 million in rewards for watching their favorite TV programs and listening to music. In addition, Viggle operates Wetpaint, which offers entertainment and celebrity news online. Viggle also operates Dijit Media, maker of technology that helps consumers search for, find, and set reminders for TV shows and movies. For more information, visit www.viggle.com or follow us on Twitter @Viggle.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. All information provided in this press release is as of June 5, 2014. Except as required by law, Viggle Inc. undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Total reach of 20.8 million is defined as the total number of registered users for the Viggle app and unique monthly users of the Wetpaint media properties.

(GWPH) Epidiolex® FDA Fast Track Designation In Dravet Syndrome

LONDON, June 6, 2014  — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to GW’s investigational cannabidiol (CBD) product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.

FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug’s development, review and potential approval to get important new drugs to the patient earlier.

“GW is focused on advancing the Epidiolex development program as rapidly as possible with the aim of addressing the significant unmet need in children suffering from Dravet syndrome. The granting of Fast Track designation, in addition to Epidiolex having already received orphan drug designation from the FDA, represents significant additional support toward this objective,” stated Justin Gover, GW’s Chief Executive Officer. “With GW having already opened an Investigational New Drug (IND) for Epidiolex, we are on track to commence a Phase 2/3 clinical trial in Dravet syndrome in the second half of this year.”

In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome (LGS). Following receipt earlier in 2014 of orphan drug designation by the FDA in LGS, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and expects to conduct two Phase 3 trials in LGS during 2015.

About Dravet syndrome

Dravet syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare and catastrophic form of epilepsy for which there is currently no cure. Seizures begin in the first year of life in an otherwise typically developing infant. Initial seizures are most often prolonged events (status epilepticus) and, in the second year of life, other seizure types emerge. All seizure types are remarkably resistant to medical therapy and the prognosis for Dravet syndrome is poor. Individuals with Dravet syndrome face a higher incidence of SUDEP (sudden unexplained death in epilepsy) and have associated co-morbid conditions, which also need to be properly managed. Children with Dravet syndrome do not outgrow this condition and it affects every aspect of their daily lives.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW’s product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding the therapeutic and commercial value of the company’s compounds including Sativex® and Epidiolex®, the development and commercialization of Sativex, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®, Epidiolex®, and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Enquiries:

         GW Pharmaceuticals plc (Today) + 44 20 3727 1000
         Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
         Stephen Schultz, VP Investor Relations (US) 401 500 6570

         FTI Consulting (Media Enquiries)
         Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
         Robert Stanislaro (US) 212 850 5657

         Trout Group, LLC (US investor relations)
         Todd James / Chad Rubin 646 378 2900

(KEYW) Partners With University of Central Florida to Provide Big Data Visualization Framework

HANOVER, Md., June 5, 2014  — The KEYW Holding Corporation (Nasdaq:KEYW) announced today that its subsidiary, The KEYW Corporation, entered into a formal partnership with the University of Central Florida (UCF) formalizing teaming efforts focused on research and development in the critical cybersecurity domain. The newly signed agreement provides KEYW and UCF with a framework to work and collaborate on task orders related to big data visualization efforts.

By establishing this broad partnership with UCF, which is a recognized academic and research leader in numerous fields such as optics, modeling and simulation, engineering, digital media, and computer science, KEYW plans to further enhance its innovative, mission-oriented cyber social media initiatives.

About KEYW

KEYW provides agile cyber superiority, cybersecurity, and geospatial intelligence solutions for U.S. Government intelligence and defense customers and commercial enterprises. We create our solutions by combining our services and expertise with hardware, software, and proprietary technology to meet our customers’ requirements. For more information contact KEYW Corporation, 7740 Milestone Parkway, Suite 400, Hanover, Maryland 21076; Phone 443-733-1600; Fax 443-733-1601; E-mail investors@keywcorp.com; or on the Web at www.keywcorp.com.

Forward-Looking Statements: Statements made in this press release that are not historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about our future expectations, plans and prospects, and other statements containing the words “estimates,” “believes,” “anticipates,” “plans,” “expects,” “will,” “potential,” “opportunities”, and similar expressions. Our actual results, performance or achievements or industry results may differ materially from those expressed or implied in these forward-looking statements. These statements involve numerous risks and uncertainties, including but not limited to those risk factors set forth in our Annual Report on Form 10-K, dated and filed March 10, 2014 with the Securities and Exchange Commission (SEC) as required under the Securities Act of 1934, and other filings that we make with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements. KEYW is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

CONTACT: Chris Donaghey
         443-733-1600

(AGTC) to Present at Upcoming Investor Conferences

GAINESVILLE, Fla., June 5, 2014 — Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will present at two upcoming investor conferences.

• Jefferies Gene Therapy Summit on Monday, June 16, 2014 in Boston. Sue Washer, President and CEO will provide a corporate overview discussing the company’s lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). In addition, Ms. Washer will participate in an ophthalmology panel Q&A hosted by Dr. Jeffery Heier, Vitreoretinal Specialist at Ophthalmic Consultants of Boston.
• Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in New York. Ms. Washer will participate in panel discussions entitled “Ophthalmology: Seeing the Future of Gene Therapy Clearly” and Dr. Jeff Chulay, Chief Medical Officer will participate in the panel “Regulatory: GMP, GCP, FDA…OKAY?”

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. AGTC’s lead product candidates, which are each in the preclinical stage, focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are rare diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments.

About X-linked Retinoschisis (XLRS)

XLRS is an inherited retinal disease caused by mutations in the RS1 gene, which encodes the retinoschisin protein. It is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity in young boys, which can progress to legal blindness in adult men.

About Achromatopsia (ACHM)

ACHM is an inherited retinal disease, which is present from birth and is characterized by the lack of cone photoreceptor function. The condition results in markedly reduced visual acuity light sensitivity causing day blindness, and complete loss of color discrimination. Best-corrected visual acuity in persons affected by ACHM, even under subdued light conditions, is usually about 20/200, a level at which people are considered legally blind.

About X-linked Retinitis Pigmentosa (XLRP)

XLRP is an inherited condition that causes boys to develop night blindness by the time they are ten and progresses to legal blindness by their early forties.

Forward Looking Statements

Statements in this press release regarding Applied Genetics Technology Corporation that do not relate to historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, financing plans, potential growth opportunities, potential market opportunities and the effects of competition, and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Readers are cautioned that these forward-looking statements are subject to risks and uncertainties and are only predictions, and actual future events and results may differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those risks and uncertainties that are discussed under “Risk Factors” in our registration statement on Form S-1 (File No. 333-193309), as amended, and our periodic and current reports filed with the SEC.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: David Carey
         Lazar Partners Ltd.
         T: (212) 867-1768
         dcarey@lazarpartners.com

         Corporate Contact:
         Larry Bullock
         Chief Financial Officer
         Applied Genetic Technologies Corporation
         T: (386) 462-2204
         lbullock@agtc.com

(MVIS) Major Global Electronics Brand to Collaborate on Display Engine for a Smartphone

MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it is collaborating with a major global consumer electronics brand to develop a display engine for use in an innovative smartphone product.

This new customer, listed on the Fortune Global 500, is a leading name in consumer electronics. The companies plan to collaborate on this development activity targeting a possible second half 2015 product introduction.

“We are extremely pleased to be working with this industry-leading electronics brand on a display engine for a truly innovative product incorporating our revolutionary PicoP display technology,” said Alexander Tokman, president and CEO of MicroVision.

This design win, which is the culmination of months of design work and technical discussions, is the second for MicroVision with a major electronics brand on the Fortune Global 500. Previously the company announced a development agreement with another global electronics brand for a custom display module incorporating PicoP^® display technology. MicroVision has announced that it is ramping up for volume production of key components with the goal to be ready in the second half of 2014.

MicroVision’s PicoPdisplay technology provides a powerful display solution that projects high-definition, focus-free content from a tiny, low-power display engine. MicroVision’s technology enables OEMs to deliver a high-quality consumer viewing experience to their customers by offering enhanced ways to view and share information. Whether for personal entertainment, social engagement, business collaboration, driver safety or in whatever way OEMs’ imaginations take them, PicoP display technology could be the exciting new element that consumers are searching for to elevate their mobile experience.

About MicroVision

MicroVision is the creator of PicoP® display technology, an ultra-miniature laser projection solution for mobile consumer electronics, automotive head-up displays and other applications. MicroVision’s patented display technology helps OEMs break down display boundaries and offer enhanced visibility to mobile experiences. Nearly two decades of research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and is also included in the Ocean Tomo 300 Patent Index. The company is based in Redmond, Wash.

For more information, visit the company’s website at www.microvision.com, on Facebook at www.facebook.com/MicroVisionInc or follow MicroVision on Twitter at @MicroVision.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to future product and technology development, introductions and sales, as well as consumer demand, and those containing words such as “plan,” “goal,” “targeting,” “possible,” and “could,” are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: our ability to raise additional capital when needed; products incorporating our PicoP display engine may not achieve market acceptance, commercial partners may not perform under agreements as anticipated, we may be unsuccessful in identifying parties interested in paying any amounts or amounts we deem desirable for the purchase or license of IP assets, our or our customers failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

(DHRM) Receives CFDA Approval for Morpheus Ox Sleep Diagnostic Software

BEIJING, June 5, 2014 — Dehaier Medical Systems Ltd. (Nasdaq:DHRM) (“Dehaier” or the “Company”), an emerging leader in development, assembly, marketing and sale of medical devices and sleep respiratory products in China, today announced that received approval from the China Food and Drug Administration (CFDA) for its Morpheus Ox software.

Dehaier Medical applied to the CFDA to register the Morpheus Ox in July 2013. With completion of this registration, we have collected all certifications for four key components of Dehaier’s Sleep Respiratory Solutions: the second generation DHR998 Sleep Diagnostic Device, photoplethysmography (PPG) sensor, sleep diagnostic software and continuous positive airway pressure ventilator in order to establish a comprehensive product line for Obstructive Sleep Apnea. Dehaier’s Morpheus Ox products assist with the diagnosis of sleep apnea, provide treatment options to apnea patients and allow post-treatment evaluation services to pinpoint further opportunities for improvement.

Dehaier Chairman and CEO Mr. Ping Chen stated, “We are confident that China’s sleep respiratory market, which is still at an early stage of development, has tremendous growth potential and that our products position us well to increase market share. Our comprehensive line of products focused on disease diagnosis, treatment and curative effect evaluation provide a one-stop solution to meet market demand. After the receipt of the fourth registration certificate for our Morpheus Ox product line, we are ready to launch the solution for sale. We showcased the Morpheus Ox System and workstation at the 2014 Third Annual Jiangxi Sleep Medicine Seminar from May 30 to 31, 2014. Based on our marketing campaign during the past couple months, we are excited to see strong interest from a variety of hospitals and physical examination centers. We are beginning to further our marketing and sales activities for our sleep respiratory products nationwide, and we expect our sleep respiratory business will grow through the rest of 2014 as we move toward mobile health care and telemedicine.”

About the Morpheus Ox System

The Morpheus Ox System is a cost-effective, portable home sleep diagnostic and monitoring solution by collecting and recording the physiological data from patients who wear the watch-sized device at home, the advanced automatic sleep scoring software makes an accurate and reliable sleep diagnosis, including Apnea Hypopnea Index (AHI), sleep/wake time, and Cheyne-Stokes breathing patterns. The new generation Morpheus Ox is a comprehensive platform that manages a cost-effective sleep services operation, including patient electronic medical records, cardiac and sleep diagnostics results, as well as complete workflow management. The web-based automatic scoring and data management are able to increase operational efficiency and provide opportunities for us to offer other services by giving users valuable and timely clinical information to improve patient treatment.

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including medical devices and sleep respiratory products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco (UK). Dehaier’s technology is based on six patents and ten software copyrights. More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

CONTACT: Dehaier Medical Systems Limited
         +86 10-5166-0080
         Surie Liu lius@dehaier.com.cn
         Janice Wang wangxq@dehaier.com.cn

(UNXL) Operational Update Call Wednesday, June 25, 2014 at 4:30 p.m. ET

(ECTE) Symphony CGM System Presentation at ADA, 74th Scientific Sessions

PHILADELPHIA, June 5, 2014  — Echo Therapeutics, Inc. (Nasdaq: ECTE) (“Echo”), a medical device company developing its Symphony^® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74^th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.

The study will be presented by the principal investigator, Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at Thomas Jefferson University in Philadelphia, PA, during poster presentations on Sunday, June 15, 2014 at 12:00 – 2:00 p.m. PT. The poster, entitled “Performance of the Symphony CGM System in Critically Ill Diabetic and Non-Diabetic Patients” (868-P), will provide an expanded analysis of data collected from the multi-center clinical trial of Echo’s Symphony CGM System in post-surgical diabetic and non-diabetic patients in hospital intensive care units (ICUs).

“The Symphony CGM System demonstrated clinically relevant accuracy and excellent safety in ICU patients. While approximately 30% of critically ill patients have a history of diabetes, poor glucose control can occur in patients with or without diabetes resulting in increased length of stay and costs,” commented Dr. Joseph. “A continuous glucose monitoring system that is safe, accurate and user-friendly will become an important clinical tool for maintaining glucose control in diabetic and non-diabetic hospitalized patients.”

Previous clinical study results of the Symphony CGM System have also been presented at various medical conferences and published in medical journals.  This May, data from an earlier study of Symphony were published in the Journal of Diabetes Science and Technology.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device, the Prelude^® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including the statement about Dr. Joseph’s poster presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s ongoing studies, including the safety and efficacy of Echo’s Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo’s Symphony CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
– Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx
– Join us on Facebook at www.facebook.com/echotx

(ADXS) National Cancer Institute Data Shows How Lm-LLO Immunotherapy Eradicates Tumors

Preclinical Research Further Suggest That Advaxis’s Lm-LLO Immunotherapy Technology Alters the Tumor Microenvironment by Increasing Cells That Are Beneficial in Fighting Tumors

PRINCETON, N.J., June 4, 2014  — Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute (NCI) reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. This research demonstrates the critical role of the tLLO peptide fusion and the strong adjuvant effect of tLLO as contributing to the increase in activated T-cells and the relative decrease in the number of Tregs in tumors, thereby increasing anti-tumor activity.

The research was conducted by Dr. Zhisong Chen, Dr. Samir Khleif and their research team at the Vaccine Branch, center for Cancer Research, NCI, NIH. The research was supported by the Intramural Research Program of the Center for Cancer Research, NCI, NIH and funded in part by Advaxis through a collaborative research and development agreement. The publication, entitled, “Episomal expression of a truncated listeriolysin O (LLO) in LmddA-LLO-E7 vaccine enhances anti-tumor efficacy by preferentially inducing CD4+FoxP3- T cell and CD8+ T cell expansion,” by Drs. Chen, Ozbun, Chong, Wallecha, Berzofsky, and Khleif, reported the complete regression of tumors in about 40% of mice after two vaccinations with ADXS-HPV. Furthermore, with the exception of one, these mice survived at least six months without relapse.

“This preclinical study conducted by researchers at the NCI further demonstrates how our proprietary Listeria-based cancer immunotherapy platform works, altering the microenvironment within the tumor to shrink, and in some cases, completely eliminating the tumor,” said Daniel J. O’Connor, Advaxis Chief Executive Officer. “Advaxis’s proprietary fusion with tLLO and the adjuvant effect of LLO in ADXS-HPV induced the strongest tumor regression.”

In this preclinical study, Advaxis’s Lm-based immunotherapies decreased the proportion of Tregs cells in tumors by causing preferential expansion of CD4+FoxP3- (activated) T cells and CD8+ Foxp3- (activated) T cells first in the blood and lymphoid tissue of the mice, and subsequently infiltrating the tumors and improving the ratio of activated T cells to Tregs inside the tumor microenvironment hereby enabling HPV targeted killer Tcells to eliminate the tumor. This activity was reported to be due to a mechanism dependent on and directly mediated by LLO, which was confirmed using a recombinant Lm where LLO was replaced with cytolysin Perfringolysin O (PFO) allowing exit of this strain from the phagolysosome.

“These results mark progress in our understanding of the potential mechanism behind the unique clinical activity of ADXS-HPV that has been associated with CRs, PRs and apparent prolonged survival as a single agent in recurrent cervical cancer in clinical trials,” commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. “The results are better than those achieved in earlier studies with different (non-Advaxis) Lm-based immunotherapies. They suggest that tLLO serves as a promising adjuvant and that its incorporation into ADXS-HPV is a critical contributor to the changes in the tumor microenvironment that favor immune killing of the tumor cells.”

ADXS-HPV is in clinical trials for three HPV-associated cancers: cervical cancer, head and neck cancer and anal cancer. Advaxis reported final Phase 2 data in recurrent cervical cancer at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and plans to move forward with a registration program in recurrent cervical cancer.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, is the only known cancer immunotherapy shown in preclinical studies to neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug status for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis’s second immunotherapy candidate is ADXS-PSA which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1 clinical study with ADXS-PSA in 2014. Advaxis is also developing ADXS-cHER2, to target the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, a model for human bone cancer. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company. Advaxis is planning to file an IND for ADXS-cHER2 in HER2 overexpressing cancers.

For more information please visit www.advaxis.com or connect with us on

• Facebook: https://www.facebook.com/advaxisinc
• Twitter: https://twitter.com/Advaxis
• LinkedIn: http://www.linkedin.com/company/advaxis-inc.
• Google+: https://plus.google.com/b/115126287957745987074/115126287957745987074/posts

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis’ proprietary immunotherapy, ADXS-HPV; whether higher doses and multiple treatment cycles of ADXS-HPV can further improve clinical outcomes and quality of life; Advaxis moving forward with a registration program in recurrent cervical cancer; the collaborative efforts of Advaxis’ licensing partners; the initiation or a registration clinical trial program for cervical cancer in 2014; Advaxis’ development of ADXS-cHER2 for both human and animal health and its pursuit of a clinical program in pediatric osteosarcoma. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACT: Advaxis Contact:
         Lisa Caperelli
         Senior Director of Investor Relations
         and Corporate Communications
         Advaxis, Inc.
         caperelli@advaxis.com
         215.206.1822

         Media Contact:
         Tiberend Strategic Advisors, Inc.
         Amy S. Wheeler
         awheeler@tiberend.com
         646.362.5750

(HALO) To Resume PEGPH20 Clinical Program In Pancreatic Cancer

FDA Removes Clinical Hold on Phase 2 Trial (Study 202)

SAN DIEGO, June 4, 2014  — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites. In May, the trial’s independent Data Monitoring Committee (DMC) recommended that enrollment and dosing in the study resume under a revised protocol.

“We are committed to the development of PEGPH20 in pancreatic cancer. Halozyme worked diligently with the FDA and the DMC to develop the plan to allow the study to restart,” commented Dr. Helen Torley, President and CEO. “We are pleased to be able to continue enrolling patients in this clinical program as there remains a significant need for new treatment options for pancreatic cancer patients.”

About Study 202
Study 202 (Halo 109-202) is a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for treatment of patients with stage IV metastatic pancreatic cancer. The primary outcome of the trial is to measure improvement in progression-free survival in patients receiving PEGPH20 in combination with gemcitabine and nab-paclitaxel compared to gemcitabine and nab-paclitaxel alone. A second primary endpoint has been added to assess the thromboembolic event rate in the PEGPH20 treatment arm following the protocol amendment. Secondary endpoints include objective response rate and overall survival. The protocol amendments to the study include the exclusion of patients who may be at higher risk of thromboembolic events. Additionally, low-molecular weight heparin will be used as a prophylaxis to prevent thromboembolic events. In addition to the over 100 patients already enrolled in the trial, Halozyme plans to enroll a similar number of additional patients.

About PEGPH20
PEGPH20 is an investigational PEGylated form of Halozyme’s proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex^® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future actions relating to the development of PEGPH20 such as the anticipated resumption of enrollment and dosing of PEGPH20 in Study 202, enrollment of additional patients in the study, and the possibility that PEGPH20 may be used to address pancreatic cancer) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including the possibility that the revised protocol may not address the apparent increased rate of thromboembolic events observed with the use of PEGPH20 in the trial or satisfy future regulatory requirements, the possibility of additional safety events, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2014.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Media Contact:
Denise Powell
510-703-9491
dpowell@brewlife.com

(DRWI) Increases Growth Expectations for First Quarter Fiscal Year 2015

Investor Contact:
John Lawlor
Investor Relations
DragonWave Inc.
jlawlor@dragonwaveinc.com
613-599-9991 ext 2424
Media Contact:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
613-599-9991 ext 2262
Media Contact:
Becky Obbema
Interprose Public Relations
(for DragonWave)
Becky.Obbema@interprosepr.com
(408) 778-2024

(LSBI) Old National Bancorp (ONB) to acquire Lafayette-based LSB

EVANSVILLE, Ind. and LAFAYETTE, Ind., June 4, 2014 —

• LSB Financial’s subsidiary, Lafayette Savings Bank, is the largest bank headquartered in Lafayette, Indiana
• Expected to be immediately accretive to 2015 earnings by $7.5 million, or $.03 per share
• Acquisition continues Old National’s strategy of regional expansion while more than doubling the bank’s presence in the economically strong Lafayette market
• Includes five banking centers in Tippecanoe County, along with $366 million in assets and $312 million in deposits
• With strong reputation and community banking-focus, Lafayette Savings Bank was voted best bank in Lafayette market the last two years (Lafayette Journal & Courier annual reader survey); Boasts a tremendous legacy – founded in 1869

Evansville-based Old National Bancorp (NASDAQ: ONB) (“Old National”) and Lafayette-based LSB Financial Corp. (NASDAQ: LSBI) (“LSB”), jointly announced today the execution of a definitive agreement under which Old National will acquire LSB Financial through a stock and cash merger.

With $366 million in total assets and just over $312 million in deposits, LSB Financial is a savings and loan holding company with Lafayette Savings Bank as its wholly-owned subsidiary. The largest bank headquartered in Lafayette, Lafayette Savings Bank currently operates five full-service banking centers in Tippecanoe County, which is home to Purdue University and a successful high-tech manufacturing sector.

Founded in Evansville in 1834, with $9.5 billion in assets and 166 branches (as of March 31, 2014), Old National is the largest financial services holding company headquartered in Indiana and the fourth largest deposit holder in the Hoosier state. Currently Old National has two banking centers in Lafayette and one in West Lafayette and others throughout Indiana, as well as banking centers in Southern Illinois, Southwestern Michigan, Western Kentucky and Louisville.

“This partnership continues Old National’s path of regional expansion by more than doubling our presence in the Lafayette market, and it also marks the union of two like-minded banks with outstanding legacies of client service and community engagement,” said Old National President & CEO Bob Jones. “By acquiring the community bank in Tippecanoe County, Old National is reinforcing our standing as the Indiana bank and one of the leading community focused banks in all of our markets.”

Randolph F. Williams, President and CEO of LSB Financial added, “Old National is an established, well-managed company that is truly Indiana’s bank; they care about the people in the markets they serve. This partnership is in the best interests of our shareholders who will become part of a larger and growing institution. Our board believes that the best way to advance our long-standing commitment to the Lafayette community is to partner with a larger institution that has demonstrated commitment to our values, is respectful of our history, and has the ability to grow opportunities for our community, customers and employees. I’m looking forward to working with Bob and his team to establish this partnership.”

Under the terms of the merger agreement, which was unanimously approved by the boards of both companies, shareholders of LSB Financial will receive 2.269 shares of Old National common stock and $10.63 in cash (fixed) for each share of LSB Financial common stock. Based upon the June 3, 2014, closing price of $13.68 per share of Old National common stock, the transaction is valued at approximately $41.67 per share of LSB Financial common stock, or approximately $66.7 million. The transaction value is likely to change due to fluctuations in the price of Old National common stock. As provided in the merger agreement, the exchange ratio is subject to adjustment (calculated prior to closing) in the event shareholders’ equity of LSB Financial is below a specified amount.

The transaction is expected to close in mid-to-late fourth quarter of 2014. It remains subject to approval by LSB Financial’s shareholders and approval by federal regulatory authorities as well as the satisfaction of other customary closing conditions provided in the merger agreement. The merger agreement also provides that Lafayette Savings Bank will be merged into Old National Bank.

Old National was advised by Keefe, Bruyette and Woods and the law firm of Krieg DeVault LLP. LSB Financial was advised by Sandler O’Neill + Partners, L.P. and the law firm of Barnes & Thornburg LLP.

About Old National

Old National Bancorp (NASDAQ: ONB) is the largest financial services holding company headquartered in Indiana. With $9.5 billion in assets as of March 31, 2014, it ranks among the top 100 banking companies in the United States. Since its founding in Evansville, Ind., in 1834, Old National Bank has focused on community banking by building long-term, highly valued partnerships with its clients. Today, Old National’s footprint includes Indiana, Western Kentucky and Louisville, Southern Illinois and Southwestern Michigan. In addition to providing extensive services in retail and commercial banking, wealth management, investments and brokerage, Old National owns Old National Insurance, one of the 100 largest brokers in the nation. For more information and financial data, please visit Investor Relations at oldnational.com.

About LSB Financial

LSB Financial Corp. (NASDAQ: LSBI) owns the largest bank headquartered in Lafayette, Indiana. Lafayette Savings Bank, FSB owns five banking centers in Tippecanoe County. It is a community-focused organization with a legacy of service that dates back to 1869. For more information, please visit Investor Relations at lsbank.com.

Conference Call

Old National will hold a conference call at 9:15 a.m. Central Time on June 4, 2014, to discuss the announced partnership with LSB Financial. The live audio web cast of the call, along with the corresponding presentation slides, will be available on Old National’s Investor Relations web page at oldnational.com and will be archived there for 12 months. A replay of the call will also be available from 7:00 a.m. Central Time on June 5 through midnight June 19. To access the replay, dial 1-855-859-2056, conference code 55912440.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the expected timing, completion, financial benefits and other effects of the proposed merger between Old National Bancorp (“ONB”) and LSB Financial Corp. (“LSB”). Forward-looking statements can be identified by the use of the words “anticipate,” “believe,” “expect,” “intend,” “could” and “should,” and other words of similar meaning. These forward-looking statements express management’s current expectations or forecasts of future events and, by their nature, are subject to risks and uncertainties and there are a number of factors that could cause actual results to differ materially from those in such statements. Factors that might cause such a difference include, but are not limited to: expected cost savings, synergies and other financial benefits from the proposed merger might not be realized within the expected time frames and costs or difficulties relating to integration matters might be greater than expected; the requisite shareholder and regulatory approvals for the proposed merger might not be obtained; market, economic, operational, liquidity, credit and interest rate risks associated with ONB’s and LSB’s businesses; competition; government legislation and policies (including the impact of the Dodd-Frank Wall Street Reform and Consumer Protection Act and its related regulations); ability of ONB and LSB to execute their respective business plans (including ONB’s pending acquisitions of LSB and United Bancorp, Inc.); changes in the economy which could materially impact credit quality trends and the ability to generate loans and gather deposits; failure or circumvention of our internal controls; failure or disruption of our information systems; significant changes in accounting, tax or regulatory practices or requirements; new legal obligations or liabilities or unfavorable resolutions of litigations; other matters discussed in this press release and other factors identified in our Annual Reports on Form 10-K and other periodic filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date of this press release, and neither ONB nor LSB undertakes an obligation to release revisions to these forward-looking statements to reflect events or conditions after the date of this press release.

Additional Information About the Old National Bancorp/LSB Financial Corp. Transaction

Communications in this document do not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed merger, Old National Bancorp (“Old National” or “ONB”) will file with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 that will include a Proxy Statement of LSB Financial Corp. (“LSB” or “LSBI”) and a Prospectus of Old National, as well as other relevant documents concerning the proposed transaction. Shareholders are urged to read the Registration Statement and the Proxy Statement/Prospectus regarding the merger when it becomes available and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information. A free copy of the Proxy Statement/Prospectus, as well as other filings containing information about Old National and LSB, may be obtained at the SEC’s Internet site (http://www.sec.gov). You will also be able to obtain these documents (when available), free of charge, from Old National at www.oldnational.com under the tab “Investor Relations” and then under the heading “Financial Information” or from LSB by accessing LSB’s website at www.lsbank.com under the heading “About” and then under the heading “Investor Relations”.

Old National and LSB and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of LSB in connection with the proposed merger. Information about the directors and executive officers of Old National is set forth in the proxy statement for Old National’s 2014 annual meeting of shareholders, as filed with the SEC on a Schedule 14A on March 14, 2014. Information about the directors and executive officers of LSB is set forth in the proxy statement for LSB’s 2014 annual meeting of shareholders, as filed with the SEC on a Schedule 14A on March 14, 2014. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the Proxy Statement/Prospectus regarding the proposed merger when it becomes available. Free copies of this document may be obtained as described in the preceding paragraph.

(ACHC) $600M Definitive Agreement to Buy Partnerships in Care

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the signing of a definitive agreement to acquire Partnerships in Care (PiC) for approximately $660 million in cash. PiC is the second largest independent provider of inpatient behavioral healthcare services in the United Kingdom, operating 23 inpatient psychiatric facilities with over 1,200 beds. For 2013, PiC produced revenue of approximately $285 million and adjusted EBITDA of approximately $75 million. Acadia has received a commitment from Bank of America Merrill Lynch regarding financing of the transaction. It is expected that Acadia will seek a combination of equity and long-term debt financing in lieu of a portion or all of the drawings under the bridge loans available in the committed financing, subject to market and other conditions. Acadia expects to complete the transaction on July 1, 2014.

Joey Jacobs, Chairman and Chief Executive Officer of Acadia, commented, “We believe our combination with PiC will be a great transaction for both Acadia and PiC. As discussed in more detail below, we believe the inpatient behavioral care market in the UK represents a very meaningful and accretive growth opportunity. As a high quality provider and well-established market leader, PiC will provide Acadia with an outstanding market entrée. We expect to support PiC’s strong management team in taking advantage of additional growth opportunities in the UK through both our access to capital and the expertise evident in the successful long-term growth record of Acadia’s management team.”

Joy Chamberlain, Chief Executive Officer of PiC, added, “We are very pleased to be joining with Acadia. We are confident that this transaction provides PiC the exact opportunity we need to expand and diversify our portfolio further to offer patients genuine choice across the spectrum of behavioral healthcare. In addition we have seen that Acadia shares our culture of compassionate care and believes, as we do, that it is the foundation of our past and future success.”

UK Behavioral Health Market Opportunity

• The independent behavioral health market represents roughly 8% of the total behavioral health market, or approximately $2 billion, and has grown at a 9.2% compound annual rate since 2004.
• This growth has been supported by the long-term decline in National Health Service (NHS) beds available for inpatient behavioral health, due both to increasing budget constraints and greater focus on quality. NHS beds for inpatient behavioral health have declined from 82% of total beds in 2004 to 69% in 2012.
• While the largest four independent inpatient behavioral health providers account for 58% of the independent behavioral health market share, including PiC with a 16% share, the remaining independent behavioral health market is highly fragmented.

Mr. Jacob’s concluded, “With a fragmented UK independent behavioral health market supported by an expanding population, higher rates of hospitalization and declining NHS bed availability, we believe this transaction with a leading, well-performing company like PiC positions the combined company to produce accretive long-term growth. As with our U.S. facilities, we see meaningful opportunities to produce organic growth in PiC’s existing facilities through the addition of new beds and service line expansions to meet areas of unmet need. We also expect to pursue additional select acquisitions in the UK and to benefit from a lower consolidated income tax rate as a result of this transaction. Assuming the transaction is completed as planned on July 1st, we expect the combined benefits of increased adjusted EBITDA and a reduced income tax rate will produce earnings accretion of approximately $0.17 to $0.20 per diluted share for the second half of 2014 and $0.40 to $0.46 per diluted share for 2015. These accretion expectations do not include the impact of any future acquisitions beyond the purchase of PiC or any transaction-related expenses.”

Investor Presentation

On June 3, 2014, representatives of the Company will be participating in the Jefferies 2014 Global Healthcare Conference. In connection with the conference, there will be an on-line web cast of the Company’s presentation available at the Company’s web site starting at 10:30 a.m. Eastern Time/9:30 a.m. Central Time on Tuesday, June 3, 2014.

The live web cast of the Company’s presentation, and slides to be discussed during the presentation, will be available on the Company’s web site, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. Please go to the site at least 15 minutes prior to the web cast to download and install any necessary software. A replay of the presentation will also be available on the Company’s web site for two weeks.

Risk Factors

This news release contains forward-looking statements. Generally words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this news release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) Acadia’s ability to complete acquisitions, including the acquisition of PiC, and successfully integrate the operations of the acquired facilities; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from the government and third-party payors; (iv) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; and (v) potential operating difficulties, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategy. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

Disclaimer

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Acadia

Acadia is a provider of inpatient behavioral healthcare services. Acadia operates a network of 52 behavioral healthcare facilities with more than 4,300 licensed beds in 24 states and Puerto Rico. Acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and therapeutic school-based programs.

(USSI) Oil Industry Veteran Gary Morris Named Board of Directors Chairman

CHATSWORTH, Calif., June 3, 2014  — US Seismic Systems^®, Inc. (USSI), a subsidiary of Acorn Energy, Inc. (NASDAQ: ACFN), is pleased to announce Mr. Gary V. Morris has been elected as the company’s new Chairman.

Mr. Morris previously served as Executive Vice President at Halliburton Company and also served as Halliburton’s Chief Financial Officer. Halliburton Company is a leading provider of oilfield services worldwide.  Appointed Executive Vice President and Chief Financial Officer in June 1997, Morris was responsible for all of Halliburton Company’s financial activities and interests, including responsibilities for all of the Shared Services support functions of the company.  Mr. Morris also led the company’s strategic planning, mergers, acquisitions and re-engineering efforts.

With over 30 years of oil related business experience, Mr. Morris is an executive with a diversified background including Oil and Gas, Oilfield Services, Engineering and Construction, Software and Insurance.  He has served in a variety of operational, financial and administration management positions in both domestic and international roles.

Subsequent to his time at Halliburton Mr. Morris served as Executive Vice President and CFO of Paradigm, a geophysical software provider.  He joined the USSI Board of Directors in December 2013.

John A. Moore, CEO of Acorn Energy said, “We are very excited to have Gary take a more active role on our team.  He shares our passion for the power of USSI’s technology to bring a new level of productivity to completions for unconventional oil producers.  He has a terrific network of decision makers and will lead our efforts to find an industry partner.”

Joe Musanti, COO of Acorn Energy, stated, “We are thrilled to have this well-known oil industry veteran as Chairman, and believe his practical experience will be very valuable as USSI continues to expand its presence in the oilfield.  Gary has very concrete ideas on how we can build shareholder value at USSI.” Mr. Musanti has been elected Vice Chairman of USSI and remains its CFO.

Gary V. Morris commented, “There is a technology race going on within the largest producers and within the largest oilfield service companies to see who can help improve production and reduce costs in both conventional and unconventional wells.  I am captivated by US Seismic and feel its technology should play a pivotal role in helping to “win the future” in the rapidly growing seismic and microseismic monitoring business.”

About US Seismic Systems, Inc.
US Seismic Systems, Inc. designs, integrates, manufactures and sells fiber-optic sensing systems and solutions for the oil and gas markets. USSI utilizes all-optical fiber sensing technology for its state-of-the-art sensors. USSI’s proprietary optical fiber and electronics combine to form the sensor system, which is designed to replace the legacy electronic-based sensor systems at a lower cost and with improved performance and reliability. For more information visit the USSI website at: www.us-si.com

About Acorn Energy, Inc
Acorn Energy, Inc. is a holding company whose four portfolio companies help their customers achieve greater productivity, reliability, security, and efficiency—factors which can lead to greater profitability.  GridSense^® provides monitoring for all critical points along the electricity delivery system. OmniMetrix™ remotely monitors emergency back-up power generation systems to increase their reliability. US Seismic Systems^® supplies fiber optic sensing solutions to increase oil/gas production and lower costs. DSIT provides security solutions from underwater threats to naval and marine based energy assets.  For more information visit: http://www.acornenergy.com.

Safe Harbor Statement

This press release includes forward-looking statements, which are subject to risks and uncertainties. There is no assurance that Acorn Energy, Inc. or its operating companies will continue to grow their respective businesses, or that any of them will meet the expectations or execute the initiatives described or referred to above. A complete discussion of the risks and uncertainties which may affect Acorn Energy’s business generally and the businesses of its subsidiaries is included in “Risk Factors” in the Company’s most recent Form 10-K filed by the Company with the Securities and Exchange Commission.

Company Contact:
F. Kent Leacock, VP Corporate Affairs
US Seismic Systems, Inc.
(925) 698-1431
kleacock@us-si.com

(SARA) Rocky 3 Well Exceeds Expectations – Test Rates over 1.5k Bbls/Day

Saratoga Resources, Inc. (NYSE MKT: SARA; the “Company” or “Saratoga”) today provided an update on its recent Rocky 3 horizontal development well in Breton Sound Block 32 field and recompletion in the QQ #24 well in Main Pass Block 47 field.

The SL 1227-29 “Rocky 3” well, in 14 feet of water depth, was spud on May 3^rd using the Parker 72B barge rig and reached a TD of 7,178’ MD/5,818’ TVD on May 15^th. The well was completed in the 5,800’ sand with a lateral displacement of 750 feet. The Rocky 3 well tested on May 30, 2014 at a gross equivalent rate of 1,531 barrels of oil per day (“BOPD”) and 240 thousand cubic feet of gas per day (“MCFPD”) , or net 1,288 barrels of oil equivalent per day (“BOEPD”), on 20/64” choke with flowing tubing pressure (“FTP”) of 780 psi. Oil gravity is 39.8 degrees API.

Saratoga’s other horizontal wells in the same field, drilled in 2013, continue to perform well with the SL 1227-25 “Rocky 1” well tested on May 27^th at a gross equivalent rate of 218 BOPD and 85 MCFPD, or net 190 BOEPD, on 28/64” choke, and the SL 1227-26 “Zeke” well tested on May 24^th at a gross equivalent rate of 152 BOPD and 17 MCFPD, or net 130 BOEPD, on 32/64” choke.

The Company also recently completed a gravel pack recompletion in the SL 195QQ-24 “Roux” well in Main Pass Block 47 field with the 19A sand perforated and completed between 8,943-53’ MD with the 20 sand between 9,172-82’ set up as a future plug down in the same wellbore. The 19A sand tested on May 30^th at a gross equivalent rate of 2,844 MCFPD and 12 BOPD, or net 350 BOEPD, on a 14/64” choke with FTP of 2,300 psi. Oil gravity is 57.0 degrees API.

Management Comments

Mr. Andrew C. Clifford, Saratoga’s President, said “The successful drilling and completion of the Rocky 3 development well in Breton Sound 32 supports our analysis that untapped development potential remains in the 5,800’ sand in the eastern part of the field, and that the application of horizontal drilling technology is a viable means of tapping undeveloped potential in many of our fields. We are in the process of identifying other horizontal well targets in the same reservoir and look to drill more wells in the field once we increase production handling capacity. Grand Bay field is another asset where we see a great potential for application of horizontal drilling technology. Horizontal wells make sense in areas with low structural dip, in fields with good well control and 3-D seismic coverage and in fields with strong water drive, all attributes applicable to Breton Sound Block 32 and Grand Bay fields. The initial production (“IP”) test rate for Rocky 3 is the highest rate for any of the Company’s wells to date as well as the highest rate for any well drilled to date in the field. We intend to produce Rocky 3 at a rate of approximately 650 BOEPD due to current capacity limitations at Breton Sound Block 32 field.”

About Saratoga Resources

Saratoga Resources is an independent exploration and production company with offices in Houston, Texas and Covington, Louisiana. Principal holdings cover 52,103 gross/net acres, mostly held by production, located in the transitional coastline and protected in-bay environment on parish and state leases of south Louisiana and in the shallow Gulf of Mexico Shelf. Most of the company’s large drilling inventory has multiple pay objectives that range from as shallow as 1,000 feet to the ultra-deep prospects below 20,000 feet in water depths ranging from less than 10 feet to a maximum of approximately 80 feet. For more information, go to Saratoga’s website at www.saratogaresources.com and sign up for regular updates by clicking on the Updates button.

Forward-Looking Statements

This press release includes certain estimates and other forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding future ability to fund the company’s development program and grow reserves, production, revenues and profitability, ability to reach and sustain target production levels, ability to secure commitments to participate in exploration of deep shelf prospects, ability to secure leases and the ultimate outcome of such efforts. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “assumes”, “seeks”, “estimates”, “should”, and variations of these words and similar expressions, are intended to identify these forward-looking statements. While we believe these statements are accurate, forward-looking statements are inherently uncertain and we cannot assure you that these expectations will occur and our actual results may be significantly different. These statements by the Company and its management are based on estimates, projections, beliefs and assumptions of management and are not guarantees of future performance. Important factors that could cause actual results to differ from those in the forward-looking statements include the factors described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update or revise any forward-looking statement based on the occurrence of future events, the receipt of new information, or otherwise.

(NFEC) Signed a Contract with Water Diversion Works to Deliver Valve Equipment

SHENYANG, China, June 3, 2014  — NF Energy Saving Corporation (NASDAQ: NFEC) (“NF Energy” or the “Company”), a leading energy saving services and solutions provider for China’s power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries, today announced that in March 2014, the Company signed two contracts with the Water Diversion Project for the buyer’s water transferring infrastructure systems among provinces in northern China.

According to the contracts, the Company is to supply the client with $15 million of butterfly valve flow control equipment. Speaking on behalf of the company, the orders will be delivered between July, 2014 and March, 2015. Mr. Gang Li, Chairman, said, “Aiming to improve the water supply for industrial and residential needs in cities and rural communities of the target regions, the Water Diversion Project is a major water works project under national planning, strategically important to regional economic development and the betterment of people’s life in northern China.”

About NF Energy Saving Corporation

NF Energy Saving Corporation (NASDAQ: NFEC) is a China-based provider of integrated energy conservation solutions utilizing energy-saving equipment, technical services and energy management re-engineering project operations to provide energy saving services to clients. The Company’s customers are mainly concentrated in the electrical generation (large-scale thermal power generation, hydroelectric power, and nuclear power), water supply, and heat supply industries. The majority of revenues are from energy efficient flow control solutions including equipment and energy efficiency project services. For more information, visit http://www.nfenergy.com.

Safe Harbor Statement

The statements contained herein that are not historical facts are considered “forward-looking statements.” Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, statements regarding the efficacy of investment in research and development are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the effect of political, economic, and market conditions and geopolitical events; legislative and regulatory changes that affect our business; the availability of funds and working capital; the actions and initiatives of current and potential competitors; investor sentiment; and our reputation. We do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events, which may cause actual results to differ from those expressed or implied by any forward-looking statements. The factors discussed herein are expressed from time to time in our filings with the Securities and Exchange Commission available at http://www.sec.gov.

Media Contact:
Andy Gao
+86-24-25609775
info@nfenergy.com

(MEIL) Selects Genscape Inc. as Its Quality Assurance Plan (QAP) Provider

(VNRX) Appoints Dr. Habib Skaff to Board of Directors

(CWCO) Declares Third Quarter Cash Dividend

(TROV) Clinical Study Results Published in 2014 ASCO Journal of Clinical Oncology

CHICAGO, June 2, 2014 — Trovagene, Inc. (NASDAQ:  TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company’s precision cancer monitoring technology, is significantly correlated with treatment response. The submission, by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, is titled “Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.”

In the study, multiple sequential urine samples were collected at least four weeks apart from 17 cancer patients with advanced disease that contained the BRAF V600E mutation. Initial mutational status was determined from tissue biopsies taken before and after patients started systemic therapy. Patients included in the study had various cancer types including melanoma (n=7), non-small cell lung cancer (n=3), colorectal cancer (n=2), and other forms of cancer (n=5). Highlights of the study results are as follows:

• Longitudinal analysis of sequential urine samples using Trovagene’s cancer monitoring assay demonstrated a highly statistically significant correlation between changes in the amount of BRAF V600E mutation load and treatment response on imaging with targeted drug therapy per RECIST 1.1 criteria (p=0.002).
• Results specifically demonstrated that patients with a decrease in BRAF V600E mutation load had a significantly longer median time to treatment failure compared to those patients who did not experience a reduction of mutation load (259 days vs. 61 days; p=0.002).

“These data suggest that detecting oncogene mutations in urinary cell-free DNA can offer a non-invasive tool for monitoring treatment effect in patients undergoing targeted cancer therapy,” stated Dr. Janku.  “The statistically significant correlation between mutational status and treatment response suggests that oncogene mutation monitoring has potential to help clinicians rapidly determine responders from non-responders, which may enable more precise treatment decisions and improved patient outcomes.”

Added Mark Erlander, Ph.D., chief scientific officer of Trovagene, “The results from this study continue to evolve and demonstrate that our molecular diagnostics can non-invasively detect and track oncogene mutations in patients with a variety of cancers and treatment regimens. Through our numerous collaborations with academic medical centers and integrated healthcare networks, we are continuing to develop the body of clinical evidence necessary to drive commercial adoption of our precision cancer monitoring platform, and to improve the standard of care for cancer patients.”

Separately, data from an expanded clinical study evaluating Trovagene’s precision cancer monitoring platform in patients with histiocytic disease for determination of mutational status and monitoring of treatment response, were presented at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago in a Poster Highlights Session and were also included in a slide presentation. The investigators intend to submit a manuscript summarizing this study for publication.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA and RNA in urine.  The company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.